Industry and academic researchers gather for innovative accelerating cancer cures research symposium
Share

South San Francisco, CA (March 29, 2018) – Yesterday, March 28, the Damon Runyon Cancer Research Foundation (Damon Runyon) held the seventh annual Accelerating Cancer Cures Research Symposium. The yearly meeting is designed to encourage collaboration between cancer researchers in industry and their counterparts in academia in order to overcome many of the issues that currently impede progress against cancer. Hosted this year by Genentech, a member of the Roche Group, the meeting included academic researchers from top universities and research institutions as well as scientists from Celgene, Eli Lilly and Company, Genentech, Gilead Sciences, Merck, and Novartis.

Accelerating Cancer Cures is a unique collaboration between Damon Runyon, a prestigious cancer charity that supports pioneering early career cancer researchers, and leading biopharmaceutical companies. The goal of this multi-million dollar initiative is to rebuild the ranks of specially trained physician-scientists who conduct both the innovative laboratory research necessary to identify new therapeutics and the clinical trials to bring these new treatments to patients. By collaborating on this initiative, the companies involved demonstrate their shared commitment to driving the next generation of breakthroughs in cancer prevention, diagnosis and treatment.

Over the past two decades, innovative cancer treatments have helped increase survival

read more...


Article originally posted at
www.eurekalert.org

Click here for the full story


CategoryAggregator News

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD